294 filings
Page 8 of 15
6-K
qplwh kov
27 Apr 18
Acasti Pharma Appoints Donald Olds to its Board of Directors and Audit Committee
8:00am
6-K
iefkf
24 Apr 18
Acasti Pharma Prices CDN$10 Million Underwritten Offering in Canada
12:00am
6-K
y9vmy2a 9m
24 Apr 18
Acasti Pharma Announces Overnight Marketed Canadian Public Unit Offering
12:00am
6-K
6dys5sm7qi7fzxb5shye
2 Apr 18
Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures
12:00am
6-K
6nn3xc bkv02qte1s
14 Mar 18
Acasti Pharma Announces First Patient Randomized in Pivotal TRILOGY Phase 3 Program
12:00am
6-K
93s7owc2b8a1202z9w32
14 Feb 18
Acasti Pharma Reports Third Quarter FY 2018 Financial Results
12:00am
6-K
uso7vis7
14 Feb 18
Current report (foreign)
12:00am
6-K
5itz gpyw8as
22 Jan 18
Acasti Pharma Announces the Closing of Over-Allotment
12:00am
6-K
upxdwaekd
16 Jan 18
Acasti Pharma Announces Change to Board of Directors
12:00am
6-K
t5uiqw67z910r3hcf
8 Jan 18
Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest Under Debentures
12:00am
6-K
o39vbpiankv6bhf
4 Jan 18
Acasti Expands Global Patent Portfolio with Newly Granted Patents in South Korea and Canada
12:00am
6-K
nt7t 2qgahdzxbt8gc
2 Jan 18
Acasti Pharma To Present at Biotech Showcase Conference
12:00am
6-K
it2e2n yi
27 Dec 17
Acasti Pharma Announces Closing of US$10 Million Firm Commitment Offering of Common Shares and Warrants
12:00am
6-K
sahuxy
21 Dec 17
Acasti Pharma Announces Pricing of US$10 Million Offering of Common Shares and Warrants
12:00am
6-K
aipixl338jmpn4
22 Nov 17
Acasti Pharma Clarifies Term of Proposed Strategic Partnership with Leading China Pharmaceutical Company
12:00am
6-K
1lp ch8ul2uf2z81l
20 Nov 17
Acasti Pharma Announces Development and Commercialization Discussions Progressing with a Leading China Pharmaceutical Partner
12:00am
6-K
1gyad
14 Nov 17
Current report (foreign)
12:00am
6-K
0bptoywr jn02
13 Nov 17
Acasti Pharma Reports Second Quarter FY 2018 Financial Results
12:00am
6-K
ya0rb9bkpdjolew561
7 Nov 17
Acasti Pharma Announces Dariush Mozaffarian, M.D., Dr.P.H. Principal Investigator for CaPre Phase 3 Development Program
12:00am
6-K
6goyx
5 Oct 17
Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures
12:00am